SRBCF News Alert Sirona Biochem Corp. (SRBCF) 0.1183 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Sirona Biochem Corp. (SRBCF) 0.1183 $SRBCF

Sirona Biochem's Subsidiary TFChem Awarded Prestigious French Innovation Trophy
Marketwired - Tue Dec 02, 6:45AM CST
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB), announces that its subsidiary TFChem has been awarded the 6th Haute-Normandie Innovation Trophy from SEINARI -- the Region Haute-Normandie innovation agency. TFChem founder, and Sirona's Chief Scientific Officer, Dr. Géraldine Deliencourt-Godefroy, accepted the award at a ceremony held November 27th in Rouen, France.
SBM.VN: 0.125 (unch)

Sirona Biochem Names Attila Hajdu as Chief Business Development Officer
Marketwired - Mon Oct 27, 6:45AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB), announces that it has named Mr. Attila Hajdu as Chief Business Development Officer. Prior to joining Sirona Biochem, Attila held various senior leadership positions within GlaxoSmithKline (GSK) and Astellas Pharma, accumulating 17 years of experience in Sales, Marketing, R&D Finance, Medical Affairs and Business Development.
SBM.VN: 0.125 (unch), GSK: 42.85 (+0.11)

Sirona Biochem Announces Research Collaboration With Aegilops Applications
Marketwired - Mon Oct 20, 6:45AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) today announced a collaboration with innovative French Company, Aegilops Applications. Aegilops specializes in the protection of plant seeds. The objective of the research collaboration is to develop a novel compound to improve germination and growth in plants, thereby enhancing crop production.
SBM.VN: 0.125 (unch)

Sirona Biochem: Obagi Medical Products Begins Manufacturing Scale-Up of Skin Lightening Agent
Marketwire - Tue Oct 07, 6:45AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) is pleased to announce that its partner Obagi Medical Products Inc., a wholly-owned subsidiary of Valeant Pharmaceuticals International, Inc., has started manufacturing scale-up of the innovative skin lightening compound (TFC-849) originally developed by Sirona's scientists in France.
SBM.VN: 0.125 (unch), VRX: 140.33 (-0.22), VRX.TO: 162.98 (-0.62)

Sirona Biochem Launches Anti-Aging Preclinical Studies
Marketwire - Mon Sep 22, 6:45AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) launches the next stage of development for its anti-aging compound library. With recent funding from Bpifrance (the French Public Investment Bank) and the district of Haute Normandie, Sirona Biochem's subsidiary TFChem (France) moves into the next phase of the agreement with the French laboratory Biogalenys.
SBM.VN: 0.125 (unch)

Sirona Biochem Announces Positive Results of PK Study for Type 2 Diabetes
Marketwire - Wed Sep 03, 3:30PM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB) today announced that Wanbang Biopharmaceuticals has successfully completed another study in the pre-clinical validation of its anti-diabetic SGLT2 Inhibitor, SBM-TFC-039, for the treatment of Type 2 diabetes.
SBM.VN: 0.125 (unch)

Sirona Biochem Launches Global Awareness Campaign With Cousteau Ambassadors' Video
Marketwire - Thu Aug 21, 2:00AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) launches global awareness campaign with ambassadors' video produced by the team of Jean-Michel Cousteau and Fabien Cousteau to represent their support of the glycoprotein project.
SBM.VN: 0.125 (unch)

Sirona Subsidiary, TFChem, Receives CDN$1.2 Million for Anti-Aging Project
Marketwire - Tue Aug 12, 6:45AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB), (the "Company" announced that its French subsidiary, TFChem, has received confirmation for funding of CDN$1.2 million from Bpifrance (the French Public Investment Bank) and the district of Haute Normandie in the form of a no-interest loan. The funds will be used to advance the organization's anti-aging project.
SBM.VN: 0.125 (unch)

Sirona Biochem Announces Successful Synthesis of Anti-Inflammatory Compound for Bloom Burton & Co. Joint Venture
Marketwire - Thu Jul 31, 6:45AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB), (the "Company" announces the achievement of the first batch of compound in the joint venture with Bloom Burton & Co. ("Bloom Burton" Compounds developed within the framework of the JV will be entering development in the areas of rare inflammatory and infectious diseases.
SBM.VN: 0.125 (unch)

Sirona Arranges Convertible Loans
Marketwire - Tue Jul 29, 4:48PM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB), (the "Company" announces that is has entered into convertible loan agreements with arm's length parties (the "Lenders" for the purposes of renewing current outstanding loans in the total amount of $670,000. The original loans were taken out in late 2012 and became due this quarter.
SBM.VN: 0.125 (unch)

Sirona Biochem Announces Successful Completion of Two First Line Studies by Wanbang Biopharmaceuticals
Marketwire - Wed Jul 23, 6:45AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM)(OTCQX: SRBCF)(FRANKFURT: ZSB) (the "Company" today announced that Wanbang Biopharmaceuticals has completed two pre-clinical efficacy studies of its SGLT2 inhibitor SBM-TFC-039. The studies independently confirm that SBM-TFC-039 increased Urinary Glucose Excretion and improved Oral Glucose Tolerance in normal SD rats. The results were consistent with those previously completed by Sirona Biochem.
SBM.VN: 0.125 (unch)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Perigon Builds Its Investment Bench for the Next Leg

Updated Category News Views 129

Perigon is rearranging the engine room before the next growth spurt gets noisy. The firm has named Christopher Broderick Director of Investments and Research, added two trading associates, and put another brick behind the broader operating structure Rafia Hasan has been assembling since taking on the chief operating officer role in August. That may sound like ordinary...

Continue Reading
Teachstone’s Bronze Award Puts Classroom Quality in Focus

Updated Category News Views 36

Small Classroom Moments Finally Get Their Due A child’s hesitant question can disappear in the noise of a busy classroom, which is precisely why Teachstone’s latest recognition deserves more than the usual polite golf clap. The Charlottesville-based Certified B Corporation received a Bronze Anthem Award for its “From Measurement to Momentum” initiative, in the...

Continue Reading
Sleep Number’s Couples Pitch Has Some Fine Print Too

Updated Category News Views 75

A thermostat war in the bedroom is a lousy reason to buy the wrong mattress. Yet that is the mundane, very real problem Sleep Number is leaning into after Expert Consumers named it a leading 2026 choice for couples seeking personalized sleep comfort. The company’s argument is straightforward: two people sharing a bed should not have to share one firmness setting, or...

Continue Reading
CASEKOO's Montana Story Makes Brand Purpose Personal

Updated Category News Views 45

A blurry Montana kitchen, not a glossy product render, is doing the heavy lifting for CASEKOO this Thanksgiving. That is either a smart bit of brand discipline or a sentimental detour, depending on whether the company can make people feel something without losing sight of why they bought a phone case in the first place. Warmth Takes the Place of Hardware CASEKOO's new...

Continue Reading
Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 100

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading
U.S. Employers Signal a Deeper Multilingual Skills Gap

Updated Category News Views 90

A language gap rarely makes the loudest noise in an earnings call, yet it can quietly wreck a sales effort, a hiring plan, or a customer relationship. ACTFL's updated 2026 employer study puts some hard edges around that problem: U.S. businesses say multilingual capability is not a nice cultural accessory. It is increasingly part of operating the business. Demand Has Moved...

Continue Reading
Childhood Nutrition Advice That Lowers Mealtime Stress

Updated Category News Views 72

A toddler surviving on three bites Tuesday is not a verdict on the family table. That plain idea sits at the center of pediatric expert Kathy Shirazi’s guidance on childhood nutrition, and frankly, it deserves more oxygen than another impossible-looking lunchbox photo. In the HelloNation article released November 20, 2026, Shirazi, MD, MPH, FAAP, urges parents to judge...

Continue Reading
North Richland Hills Bets on Its Visitor Momentum Now

Updated Category News Views 65

A crowded family attraction map is a nice problem for a Texas city to have, and North Richland Hills is trying to turn that pile of assets into a cleaner regional tourism machine. On Nov. 20, 2026, the city introduced “The Place You Never Outgrow,” its first destination-marketing campaign, built with Flat Five Marketing. This is not a stock story in the usual...

Continue Reading
Digital Diabetes Care Has a Bigger Prize Than Devices

Updated Category News Views 121

A glucose sensor is becoming less a gadget than a running conversation between patient, clinician and software. That shift matters because diabetes management is leaving the occasional clinic visit and moving into daily life, where the useful product is not merely a reading but a pattern someone can act on. The sector deserves attention from investors, but it also...

Continue Reading
S&P Global's UBS AI Conference Slot Deserves Attention

Updated Category News Views 88

Thirty Minutes Can Still Matter A half-hour fireside chat is not a quarterly earnings call, and anybody treating it like one is setting themselves up for disappointment. Still, S&P Global CEO Martina Cheung appearing at the UBS Global Technology and AI Conference on December 2 deserves a spot on the calendar for owners of NYSE:SPGI. This is a company sitting in the middle...

Continue Reading

Top 5 Most Recently Viewed Articles

Specialty1 Partners Drives New Growth Through Partnerships

Updated Category News Views 227

Specialty1 Partners Fuels Growth with Innovative Model Specialty1 Partners (S1P) has emerged as a leader in the specialty dental partnership sector, focusing on aiding Endodontists, Periodontists, and Oral Surgeons in elevating their practices. Their innovative joint venture model is increasingly attracting dental specialists eager to transition from associates to...

Continue Reading
Union Pacific in Talks for Major Norfolk Southern Merger

Updated Category News Views 263

Union Pacific's Ambitious Merger Talks Union Pacific Corp. (NYSE: UNP) is reportedly engaged in preliminary discussions to acquire Norfolk Southern Corp. (NYSE: NSC), marking a prospective mega-merger in the railroad industry. While details are still emerging, the implications of such a merger could significantly reshape the freight transport landscape across the United...

Continue Reading
Great Elm Capital Corp.'s Impressive Second Quarter Performance

Updated Category News Views 147

Overview of Financial Achievements Great Elm Capital Corp. (NASDAQ: GECC) has recently released its financial performance report for the second quarter, demonstrating remarkable growth and a prosperous quarter for the company. This update is essential for investors and stakeholders keen on understanding the company's current financial health and future prospects. Record...

Continue Reading
Scandinavian Tobacco Group Updates on Share Buy-back Activities

Updated Category News Views 211

Scandinavian Tobacco Group A/S launched a significant share buy-back program back in November, worth up to DKK 850 million. The move aimed at adjusting the company's capital structure and meeting obligations tied to its share-based incentive programs. This isn’t just a random act; it’s a strategic ploy in a competitive market that’s meant to bolster their stock...

Continue Reading
Breakthrough Outcomes of Telitacicept in Sjögren's Syndrome Study

Updated Category News Views 220

Exciting Developments in Telitacicept Phase III Trial Results The Phase III clinical trial results for Telitacicept are sparking significant interest, particularly within the realm of Sjögren's Syndrome. This autoimmune condition can severely affect patients' quality of life due to symptoms like dry mouth and dry eyes, among others. Recently, announcements surrounding...

Continue Reading